[Breast cancer treated with primary chemotherapy: predictive factors for radical treatment (retrospective study of 72 cases)].
Cancer du sein traité par chimiothérapie première: facteurs prédictifs du traitement radical (étude rétrospective à propos de 72 cas).
Breast cancer
chemotherapy
mastectomy
predictive factors
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
06
2020
accepted:
02
07
2020
entrez:
21
9
2020
pubmed:
22
9
2020
medline:
7
1
2021
Statut:
epublish
Résumé
Neoadjuvant chemotherapy has become the first-line treatment for locally advanced breast cancers. On the one hand, it allows for increasing options of breast conservation without an increased risk of recurrence, on the other hand it allows for locoregional control of patients with inoperable cancer. However, some clinical, radiological and histological factors are associated with an increased risk of mastectomy, such as microcalcifications, multifocality, SBR1 and 2 grade, cT3 and cT4 stages and overexpressed HER2. The purpose of this study was to determine the predictive factors for mastectomy after neoadjuvant chemotherapy (NAC), whether mastectomy was justified or not histologically and what were the predictors for unjustified mastectomy. We conducted a retrospective study of 72 patients with breast cancer treated by neoadjuvant chemotherapy in the Departments of Gynecology and Medical Oncology at the Fattouma Bourguiba Hospital in Monastir, Tunisia. The rate of conservative treatment was 18.1%; 63.15% for stage T2 tumors. Mastectomy was not justified by definitive histologic diagnosis in 26.3% of cases. In our study, unjustified mastectomy predictors were negative RH status and CT2 stage. This study led to reflection on our practice and its modifications. Conservative surgery should be considered as standard therapy and should be routinely suggested to all patients treated with neoadjuvant chemotherapy for breast cancer, including the cases with multifocality, large clinical tumor size, extensive microcalcifications, in order to significantly reduce the number of unjustified mastectomies.
Identifiants
pubmed: 32952818
doi: 10.11604/pamj.2020.36.174.24036
pii: PAMJ-36-174
pmc: PMC7467888
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
174Informations de copyright
Copyright: Ahmed Hajji et al.
Déclaration de conflit d'intérêts
Les auteurs ne déclarent aucun conflit d’intérêts.
Références
J Natl Cancer Inst. 2000 Jul 19;92(14):1143-50
pubmed: 10904087
Ann Oncol. 1991 May;2(5):347-54
pubmed: 1954179
J Clin Oncol. 2001 Sep 15;19(18):3828-35
pubmed: 11559720
J Clin Oncol. 2006 Nov 1;24(31):4971-5
pubmed: 17075114
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Breast Cancer Res Treat. 2011 May;127(1):121-8
pubmed: 20848185
Ann Oncol. 1999 Jan;10(1):47-52
pubmed: 10076721
Surg Today. 2000;30(3):249-54
pubmed: 10752778
Breast Cancer Res Treat. 2009 Feb;113(3):577-83
pubmed: 18330695
Cancer. 2004 Sep 1;101(5):918-25
pubmed: 15329898
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lancet Oncol. 2001 Sep;2(9):561-70
pubmed: 11905711
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
N Engl J Med. 2002 Oct 17;347(16):1233-41
pubmed: 12393820
Ann Surg Oncol. 2011 Dec;18(13):3797-801
pubmed: 21630123